What You Need to Know at This Stage of the Coronavirus Vaccine Race
We are nearing the final stage of what may be the world's most-watched race. And I'm not referring to the U.S. presidential election. I'm referring to the race to develop a COVID-19 vaccine. As of now, 10 programs are involved in phase 3 studies.
And in a few days, a U.S. Food and Drug Administration (FDA) meeting may offer clues as to what will happen next. The Vaccines and Related Biological Products Advisory Committee will meet Oct. 22 to discuss studies that should be performed to further confirm vaccine candidates' safety and efficacy (whether pre- or post-approval).
In a briefing document, the FDA emphasized that any emergency use authorization (EUA) must be supported by phase 3 data. And the agency said that prior to granting an EUA, the committee would meet for an open session to consider that data. With the finish line now on the horizon, investors may be wondering which players have the best chance of winning the much-desired EUA. Let's take a closer look at where some of the leaders stand.
Source Fool.com
